EHA 2018 | Haploidentical vs. unrelated transplants in DLBCL
Stem cell transplants are one of the most well-studied and effective therapies for blood cancers. In this video, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the objectives and results of recent studies carried out in collaboration by the CIBMMTR-LC and the EMBT-LWP. Two different donors were used to source the stem cells, donors that were haploidentical to the patients and donors who were unrelated, and the results were compared with each other in terms of PFS, mortality and relapse rate. Although no conclusive evidence has been presented as of yet, the information presented by Dr Sureda at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, has the potential to refine stem cell transplants and improve overall patient survival.
